KR102501827B1 - 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼 - Google Patents

바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼 Download PDF

Info

Publication number
KR102501827B1
KR102501827B1 KR1020197010798A KR20197010798A KR102501827B1 KR 102501827 B1 KR102501827 B1 KR 102501827B1 KR 1020197010798 A KR1020197010798 A KR 1020197010798A KR 20197010798 A KR20197010798 A KR 20197010798A KR 102501827 B1 KR102501827 B1 KR 102501827B1
Authority
KR
South Korea
Prior art keywords
cells
virus
antigen
peptides
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197010798A
Other languages
English (en)
Korean (ko)
Other versions
KR20190051039A (ko
Inventor
클리오나 엠. 루니
도일 나탈리아 렙테바
산드히야 샤르마
디미트리오스 와그너
Original Assignee
베이롤 칼리지 오브 메드신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이롤 칼리지 오브 메드신 filed Critical 베이롤 칼리지 오브 메드신
Publication of KR20190051039A publication Critical patent/KR20190051039A/ko
Application granted granted Critical
Publication of KR102501827B1 publication Critical patent/KR102501827B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020197010798A 2016-09-16 2017-09-13 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼 Active KR102501827B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395438P 2016-09-16 2016-09-16
US62/395,438 2016-09-16
PCT/US2017/051284 WO2018052947A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells

Publications (2)

Publication Number Publication Date
KR20190051039A KR20190051039A (ko) 2019-05-14
KR102501827B1 true KR102501827B1 (ko) 2023-02-22

Family

ID=61619728

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010798A Active KR102501827B1 (ko) 2016-09-16 2017-09-13 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼

Country Status (10)

Country Link
US (2) US20190194619A1 (https=)
EP (1) EP3512531A4 (https=)
JP (1) JP7002769B2 (https=)
KR (1) KR102501827B1 (https=)
CN (1) CN110177558B (https=)
AU (1) AU2017326173B2 (https=)
CA (1) CA3036966A1 (https=)
NZ (1) NZ751571A (https=)
TW (1) TWI780069B (https=)
WO (1) WO2018052947A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
US9642906B2 (en) * 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
TW202011977A (zh) * 2018-04-20 2020-04-01 貝勒醫學院 溶瘤病毒療法及免疫療法
CN108841792A (zh) * 2018-06-14 2018-11-20 浙江大学 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
ES3000183T3 (en) * 2018-09-10 2025-02-27 Atara Biotherapeutics Inc Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US10772914B1 (en) * 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
WO2022056285A1 (en) * 2020-09-10 2022-03-17 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
EP4048402A4 (en) * 2019-10-23 2023-11-22 Cue Biopharma, Inc. MODIFIED CYTOTOXIC T CELLS AND METHOD OF USE THEREOF
WO2021101466A1 (en) * 2019-11-19 2021-05-27 Acibadem Labmed Sağlik Hi̇zmetleri̇ A.Ş. A method for producing multivirus specific t cells
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
CN116391030A (zh) * 2020-10-28 2023-07-04 Tsd 生命科学有限公司 诱导异质免疫细胞趋化的转化免疫细胞
CN117529551A (zh) 2021-04-27 2024-02-06 贝勒医学院 表达嵌合抗原受体的病毒特异性免疫细胞
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
KR20250024750A (ko) 2022-04-13 2025-02-19 티크바 알로셀 피티이. 엘티디. 치료용 t 세포 산물
EP4509137A1 (en) * 2023-06-14 2025-02-19 Kuiper, Inc. A chimeric antigen receptor combinatorial multi-antigen targeted allogeneic t cell immunotherapy with reduced risk of t cell exhaustion, host versus graft rejection, and graft versus host disease
GB202318977D0 (en) * 2023-12-12 2024-01-24 Swarm Oncology Ltd Method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155594A1 (en) 2001-03-27 2002-10-24 Hsieh Helen V. Method and apparatus for culturing cells
US20150017723A1 (en) 2011-12-12 2015-01-15 Cell Medica Limited Process of expanding t cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1941028A2 (en) 2005-08-08 2008-07-09 Fondazione Centro San Raffaele Del Monte Tabor Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
CA2682527C (en) * 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP2065462A1 (en) * 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
CN103002915B (zh) * 2010-04-13 2015-09-23 免疫创新治疗有限公司 抑制Treg细胞的方法和组合物
PT2812431T (pt) * 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
KR101545217B1 (ko) * 2012-10-29 2015-08-18 연세대학교 산학협력단 줄기세포의 미분화 배양 및 분화 증진을 위한 폴리도파민-펩타이드 고정화 표면 기질 및 그 제조 방법
CN105335280A (zh) * 2014-07-16 2016-02-17 北京奇虎科技有限公司 程序性能测试方法和装置
CN107002084B (zh) 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US12478670B2 (en) * 2015-03-20 2025-11-25 Children's National Medical Center Generating HPV antigen-specific T cells from a naïve T cell population
JP7284556B2 (ja) * 2015-05-12 2023-05-31 メモリアル スローン ケタリング キャンサー センター Ｔ細胞療法によるエプスタイン－バーウイルス関連リンパ増殖性障害の治療方法
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
MX2019000022A (es) * 2016-06-27 2019-09-18 Yeda Res & Dev Células veto generadas a partir de linfocitos t de memoria.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155594A1 (en) 2001-03-27 2002-10-24 Hsieh Helen V. Method and apparatus for culturing cells
US20150017723A1 (en) 2011-12-12 2015-01-15 Cell Medica Limited Process of expanding t cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lam, S. et al., JPT PepMixTM ULTRA Peptide Pool Application Note (2015)*
Teschner, D. et al., Bone Marrow Transplantation (2013) 49(1):138-144*

Also Published As

Publication number Publication date
NZ751571A (en) 2025-10-31
AU2017326173B2 (en) 2022-08-18
KR20190051039A (ko) 2019-05-14
CN110177558B (zh) 2025-02-28
US20220251509A1 (en) 2022-08-11
TW201814041A (zh) 2018-04-16
CA3036966A1 (en) 2018-03-22
EP3512531A1 (en) 2019-07-24
AU2017326173A1 (en) 2019-04-11
JP7002769B2 (ja) 2022-02-04
EP3512531A4 (en) 2020-03-11
JP2019531722A (ja) 2019-11-07
WO2018052947A1 (en) 2018-03-22
TWI780069B (zh) 2022-10-11
US20190194619A1 (en) 2019-06-27
CN110177558A (zh) 2019-08-27

Similar Documents

Publication Publication Date Title
KR102501827B1 (ko) 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼
US11981923B2 (en) Pepmixes to generate multiviral CTLS with broad specificity
US10500265B2 (en) Generation of HPV-specific T-cells
CN111163758A (zh) 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂
JP2025028931A (ja) Ｅｂｖ特異的免疫細胞
WO2020112815A1 (en) Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
JP2022554217A (ja) 養子免疫療法
NZ791258A (en) Platform for activation and expansion of virus-specific t-cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000